Skip to main content

Table 2 Prevalence of different anti-phospholipid antibodies (aPLs) among patients with the antiphospholipid syndrome (APS) and controls

From: Profiles of criteria and non-criteria anti-phospholipid autoantibodies are associated with clinical phenotypes of the antiphospholipid syndrome

APLs

APS patients

N = 130

All controls

N = 58

p value

APS vs All controls

Healthy controls (HC)

N = 40

p value

APS vs HC

Sepsis patients (SP)

N = 18

p value

APS vs SP

CL

IgM

34 (26%)

1 (2%)

0.001

0

< 0.001

1 (5%)

0.07

IgG

77 (59%)

1 (2%)

0.001

0

< 0.001

1 (5%)

< 0.001

P-acid

IgM

17 (13%)

0

0.001

0

< 0.05

0

NS

IgG

73 (56%)

0

0.001

0

< 0.001

0

< 0.001

PE

IgM

4 (3%)

0

NS

0

NS

0

NS

IgG

3 (2%)

0

NS

0

NS

0

NS

PG

IgM

4 (3%)

0

NS

0

NS

0

NS

IgG

50 (38%)

0

0.001

0

< 0.001

0

< 0.001

PI

IgM

11 (8%)

0

0.01

0

0.06

0

NS

IgG

59 (45%)

1 (2%)

0.001

1 (2%)

< 0.001

0

< 0.001

PS

IgM

16 (12%)

0

0.003

0

< 0.05

0

NS

IgG

73 (56%)

0

0.001

0

< 0.001

0

< 0.001

AN

IgM

2 (1%)

1 (2%)

NS

0

NS

1 (5%)

NS

IgG

36 (27%)

5 (9%)

0.003

2 (5%)

< 0.01

3 (16%)

NS

β2GP1

IgM

42 (32%)

6 (10%)

0.003

4 (10%)

< 0.001

2 (10%)

NS

IgG

86 (66%)

5 (9%)

0.001

1 (2%)

< 0.001

4 (22%)

< 0.001

PT

IgM

2 (1%)

0

NS

0

NS

0

NS

IgG

40 (30%)

1 (2%)

0.001

0

< 0.001

1 (5%)

< 0.05

  1. HC healthy controls, SP sepsis patients, CL cardiolipin, β2GP1 beta2-glycoprotein1, P-acid phosphatidic acid, PC phosphatidylcholine, PE phosphatidylethanolamine, PG phosphatidylglycerol, PI phosphatidylinositol, AN annexin 5, PS phosphatidylserine, PT prothrombin, NS non-significant